AIM Vaccine announced on November 1st that the company's independently developed 13-valent conjugate pneumonia vaccine has submitted an application for drug market registration to the National Medical Products Administration. The group's wholly-owned subsidiary, AIM Persistence Biopharmaceutical Co., Ltd., has obtained the corresponding drug production license to produce this product. The launch of this vaccine is imminent, and after its launch, AIM will become an important global supplier of the 13-valent conjugate pneumonia vaccine, significantly enhancing the company's performance.

The completed unblinding Phase III clinical study results show that AIM's 13-valent conjugate pneumonia vaccine has good immunogenicity and safety, achieving the preset clinical goals.

According to the World Health Organization's classification, pneumococcal disease is one of the diseases with an extremely high priority for prevention using vaccines. According to Pfizer's 2023 annual report, Pfizer's conjugate pneumonia vaccine had global sales of about $6.44 billion in 2023. In addition, the penetration rate of the 13-valent conjugate pneumonia vaccine in the approved age group in China is estimated to be 25.9%, while the corresponding age group in the United States has a penetration rate of over 80%, indicating a huge upward space in the Chinese market. The domestic sales of this product in 2022 were about 9.5 billion yuan, and according to China Insights Consultancy (CIC)'s forecast, the market size is expected to reach 35 billion yuan by 2030.

In the strong rebound of the Hong Kong stock pharmaceutical sector since October, AIM Vaccine has led the sector in gains for several consecutive trading days, with data showing that large funds are rushing in to seize shares. Bank of Communications International stated that considering the sector's valuation was already at a historical bottom, there is still room for further repair.